Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
23 Ottobre 2023 - 1:00PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus, today
announced the Company will host a conference call and live audio
webcast on Monday, November 13, 2023, at 4:30 p.m. ET to report
third quarter 2023 financial results and provide a corporate
update.
To participate in the conference call, please
register here. Registrants will receive the dial-in numbers and a
unique PIN.
A live audio webcast and archived replay of the
call will be available under “Events & Presentations” in the
Investors section of the Company’s website at
www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s KORSUVA® (difelikefalin) injection is the first and only
FDA-approved treatment for moderate-to-severe pruritus associated
with chronic kidney disease in adults undergoing hemodialysis. The
Company is developing an oral formulation of difelikefalin and has
Phase 3 programs ongoing for the treatment of pruritus in patients
with advanced chronic kidney disease and atopic dermatitis. In
addition, the Company has an ongoing Phase 2/3 program of oral
difelikefalin for the treatment of moderate-to-severe pruritus in
patients with notalgia paresthetica. For more information, visit
www.CaraTherapeutics.com and follow the company on X (Twitter),
LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Grafico Azioni Cara Therapeutics (NASDAQ:CARA)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Cara Therapeutics (NASDAQ:CARA)
Storico
Da Mag 2023 a Mag 2024